25 February 2021 - Submission for entering the world’s largest US marketplace. ...
1 March 2021 - In addition, LFB announces the online publication of the exploratory in vitro study results on eptacog beta ...
24 February 2021 - Submission is eligible for priority review and accelerated approval. ...
18 February 2021 - Efanesoctocog alfa, previously known as BIVV001, is an investigational factor VIII replacement therapy that has the potential ...
14 February 2021 - Repeal of NDP bill last fall clears way for Canadian Plasma Resources to set up shop. ...
12 February 2021 - The first and only FDA approved intravenous immunoglobulin with two maintenance dosing options for chronic inflammatory ...
2 December 2020 - Catalyst Biosciences today announced the U.S. FDA has granted fast track designation for marzeptacog alfa (activated) – ...
9 November 2020 - PDUFA date extended by FDA from 5 March 2021 to 5 June 2021. ...
30 October 2020 - Today the EMA has implemented two further extra transparency measures for COVID-19 medicines, by publishing both ...
28 October 2020 - Initial agreement for 300,000 vials with potential for purchase of an additional 650,000 vials. ...
20 October 2020 - All the weak points of American health care — testing delays, communication breakdowns, inequity — are working ...
19 October 2020 - Octapharma is pleased to announce that the U.S. FDA has approved an updated Prescribing Information for Nuwiq, ...
7 October 2020 - The company said that doses of the unproven treatment would be available for 50,000 patients. It’s impossible ...
28 September 2020 - Haegarda is the first and only subcutaneous prophylactic hereditary angioedema treatment approved for children 6 years of ...
25 September 2020 - The costs of factor IX concentrate, which is used in the treatment of haemophilia B, are reduced ...